Investigating the adverse respiratory effects of beta-blocker treatment: Six years of prospective longitudinal data in a cohort with cardiac disease

Internal Medicine Journal

Volumn 42, Issue 7, 2012, Pages 786-793

  Cochrane, B ^a,b,d   Quinn, S ^e   Walters, H ^d   Young, I ^c  

^a CAMPBELLTOWN HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Adrenergic; Beta blocker; COPD; Disease exacerbation; Heart disease; Undesirable effect

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; CARDIOLOGIST; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART DISEASE; HIGH RISK PATIENT; HUMAN; LONGITUDINAL STUDY; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; SPIROMETRY; SURVIVAL; SYMPTOM; TREATMENT OUTCOME; WHEEZING;

EID: 84864042652     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02563.x     Document Type: Article

References (16)

1. Herlitz J, Holmberg S, Pennert K, Swedburg K, Vedin A, Waagstein F etal. Goteborg Metoprolol Trial: design, patient characteristics and conduct. Am J Cardiol 1984; 53: 3D-8D.
2. Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
3. Sin D, Man S. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
4. Hole D, Watt G, Davey-Smith G, Hart C, Gillis C, Hawthorne V. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-15.
5. Mannino D, Davis K. Lung function decline and outcomes in an elderly population. Thorax 2006; 61: 472-7.
6. Engstrom G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers - an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 2000; 7: 267-72.
7. Raine J, Palazzo M, Kerr J, Sleight P. Near fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. BMJ 1981; 282: 548-9.
8. Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 2: CD003566.
9. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002; (1): CD002992.
10. Anonymous. Standardisation of spirometry: 1994 update, American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-36.
11. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1256-76.
12. Buist AS, Vollmer W, Weiss KB. Burden of Obstructive Lung Disease (BOLD). Portland: University of Oregon; 2004.
13. Morris J, Koski A, Johnson L. Spirometric standards for health non-smoking adults. Am Rev Respir Dis 1971; 103: 57-67.
14. Welch BL. On the comparison of several mean values: an alternative approach. Biometrika 1951; 38: 330-6.
15. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157: 940-3.
16. Rutten F, Zuithoff N, Hak E, Grobbee D, Hoes A. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7.